EUVIMEDDescoperă EUVIMED
Crossref

Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile

Kathleen I Pishas iD, Karla J Cowley, Evanny Marinovic iD, Martin Köbel iD, Marta Llaurado-Fernandez, Hannah Kim, Shaine Chenxin Bao iD, Dalia Mizikovsky iD, Nathan J Palpant iD, Raunak Shrestha iD, Robert Vary iD, Jennii Luu iD and 9 more

The Journal of Pathology · 2026

DOI: 10.1002/path.70075 ↗

At a glance

Journal article in The Journal of Pathology, 2026. Written by Kathleen I Pishas and 20 co-authors. Institution: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Major MEDLINE topics: Ovarian Neoplasms, Cystadenocarcinoma, Serous, Protein Kinase Inhibitors, Antineoplastic Agents. Cited 1 times so far (Crossref); 46 references. Funded by: Therapeutic Innovation Australia, Ovarian Cancer Research Foundation, U.S. Department of Defense.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Low‐grade serous ovarian carcinoma (LGSOC) is a rare, indolent ovarian cancer subtype with limited effective therapies. Approximately 40% of cases lack canonical MAPK/ERK or PI3K/AKT/mTOR pathway alterations and are classified as having no specific molecular profile (NSMP). These patients have poor responses to chemotherapy, MEK inhibitors, and hormonal therapies, highlighting the need for alternative strategies. This study aimed to identify novel therapeutic targets in NSMP LGSOC. A high‐throughput drug screen of 3,436 compounds (including FDA‐approved, clinically tested, and investigational agents) was conducted across 12 LGSOC and one control ovarian epithelial cell line. EGFR inhibitors emerged as selective hits in NSMP cell lines and were further tested in two NSMP and two MAPK‐mutant lines in combination with standard‐of‐care chemotherapy agents, carboplatin and paclitaxel. EGFR expression was assessed using RNA sequencing, DNA methylation profiling, and immunohistochemistry in primary tumors, followed by survival analysis based on expression levels. Unsupervised clustering of drug response data revealed subtype‐specific vulnerabilities, with EGFR inhibitors showing marked cytotoxicity in all five NSMP lines (robust Z ‐score ≤ −2), and minimal activity in MAPK‐ and USP9X ‐mutant lines. EGFR inhibitors (avitinib, AV‐412) showed selective, low‐dose synergy with standard‐of‐care chemotherapy in NSMP models, with minimal and inconsistent effects in MAPK‐mutant lines. NSMP tumors showed elevated EGFR mRNA and EGFR protein expression, associated with poor survival, advanced disease stage, and peritoneal involvement, and inversely correlated with MAPK mutations. These findings position EGFR overexpression as a defining and targetable feature of NSMP LGSOC and support further preclinical validation of EGFR inhibitors as a treatment strategy for this understudied cancer subtype. © 2026 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Ovarian NeoplasmsCystadenocarcinoma, SerousProtein Kinase InhibitorsAntineoplastic AgentsFemaleHumansErbB ReceptorsCell Line, TumorSignal TransductionMolecular Targeted TherapyNeoplasm GradingBiomarkers, Tumor

Substances

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanAntineoplastic AgentsBiomarkers, Tumor

Authors and institutions

  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Clinical Research, BC Cancer, Vancouver, British Columbia, Canada.

ORCID profiles: Kathleen I Pishas, Evanny Marinovic, Martin Köbel, Shaine Chenxin Bao, Dalia Mizikovsky, Nathan J Palpant, Raunak Shrestha, Robert Vary, Jennii Luu, Liliane Meunier, Timothy Semple, Pilar Blancafort, Paul A Cohen, Ian G Campbell, Kaylene J Simpson, Dane Cheasley

Funding

  • Therapeutic Innovation Australia
  • Ovarian Cancer Research Foundation
  • U.S. Department of Defense
  • Medical Research Future Fund
  • Victorian Cancer Agency
  • Australian Cancer Research Foundation
  • Peter MacCallum Cancer Centre Foundation
  • University of Melbourne Collaborative Research Infrastructure Program

Cite

APA

Pishas, K. I., Cowley, K. J., Marinovic, E., Köbel, M., Llaurado-Fernandez, M., Kim, H., Bao, S. C., Mizikovsky, D., Palpant, N. J., Shrestha, R., Vary, R., Luu, J., Meunier, L., Semple, T., Blancafort, P., Golden, E., Cohen, P. A., Carey, M. S., Campbell, I. G., …, & Cheasley, D. (2026). Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile. The Journal of Pathology. https://doi.org/10.1002/path.70075

Vancouver

Pishas KI, Cowley KJ, Marinovic E, Köbel M, Llaurado-Fernandez M, Kim H, et al. Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile. The Journal of Pathology. 2026. doi:10.1002/path.70075

BibTeX
@article{Pishas2026,
  author = {Pishas, Kathleen I and Cowley, Karla J and Marinovic, Evanny and Köbel, Martin and Llaurado-Fernandez, Marta and Kim, Hannah and Bao, Shaine Chenxin and Mizikovsky, Dalia and Palpant, Nathan J and Shrestha, Raunak and Vary, Robert and Luu, Jennii and Meunier, Liliane and Semple, Timothy and Blancafort, Pilar and Golden, Emily and Cohen, Paul A and Carey, Mark S and Campbell, Ian G and Simpson, Kaylene J and Cheasley, Dane},
  title = {Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile},
  journal = {The Journal of Pathology},
  year = {2026},
  doi = {10.1002/path.70075}
}
Start for free →